Coordinated with CROs to plan and execute IND-enabling pharmacokinetic and toxicology studies Analyzed, translated, presented pharmacokinetic and toxicology study data from CROs to the company in non-scientific terminology

Worked with vendors to order and establish a new neuro oncology laboratory Utilized lab techniques, such as: tissue culturing of primary and immortal glioblastoma and breast cancer cells line, 5 color flow cytometry, immunoassays, ELISAs, and mini preps Worked with PI and collaborators to write multiple grants, and worked with department administration to put together additional non-science documents to ensure high-quality grant applications were submitted Presented data from projects in 4 poster presentations and 1 seminar Managed multiple projects at once, and mentored 3 undergraduates and 1 pediatric neurology resident Used Benchling in plasmid design, employed LabArchives electric lab notebook (ELN) for accurate record keeping, and analyzed data using Graphpad Prism and Flowjo Wrote and maintained the lab institutional biosafety committee protocol Scheduled weekly lab meetings and additional meetings when needed Worked with institutional administration to set up material transfer agreements (MTAs) and non-disclosure agreements (NDAs) Data generated will result in at least 2 co-author publications

Developed protocols and methods for the development of chimeric antigen receptor T (CAR-T) cell therapies to treat multiple myeloma and various lymphoma cancersDesigned and developed 4 novel, single chain bispecific antibodies capable of reducing manufacturing costs and time by more than 60%, and significantly increasing potency compared to the lab’s previous generation of bispecific antibodiesWrote and filed invention disclosures for 1 of the CAR-T therapies, and 2 of the novel bispecific antibodies, resulting in patents being filed for both bispecific antibodiesUtilized lab techniques, such as: isolating T cells from whole blood, tissue culturing of primary and immortal T cells lines, chromium51 release cytotoxicity assays, cloning, subcloning, 3 color flow cytometry, antigen quantification assays, electroporation, column chromatography, and immunoassays Produced, purified, titered, and transduced CAR-T lentiviruses into immortal and primary human cell linesWorked to develop an allogenic T cell model to reduce CAR-T production time and costs by using a multiplexed CRISPR plasmid to knockout TCR genes and differentiate iPSCs to T cellsUsed Benchling in plasmid design, employed LabArchives electric lab notebook (ELN) for accurate record keeping, and analyzed data using Graphpad Prism and FlowjoServed as a member on the MCW Postdoctoral Advisory Committee, and chaired both the onboarding (2020-2021) and website design (2021-present) sub-committeesManaged multiple projects at once, and mentored more than 15 undergraduates and junior staff in the labServed as a reviewer for the MCW excellence in science award, the MCW outstanding female postdoc award, the MCW postdoc mentor award, and MCW’s honors research programPresented data from projects in 10 poster presentations and 1 seminar

● Develop assay protocols for monoclonal antibodies and gene therapies, manage the lab via ordering, maintenance, and record keeping, and mentor more than 14 junior and pre-candidacy PhD students in the lab and classroom● Perform molecular cloning and use behavioral & biodistribution assays, tail bleeds, and subcutaneous (s.c.) dosing in mouse models ● Analyze western-blots using LICor ImageStudio, use Serial Cloner in plasmid construct design, employ Labguru Electronic Lab Notebook (ELN) for accurate record keeping, and analyze data using Graphpad Prism● Designed, cloned, and characterized 3 iterations of an anti-methamphetamine (meth) monoclonal antibody-based gene therapy to aid in meth abuse recovery● Increased the circulating concentrations of final scFv-Fc fusion protein 30-fold over original construct design; resulted in prevention of psychostimulant effects of meth at high doses (10 mg/kg, s.c.) in mouse models● Presented data from project in 24 poster presentations, 8 seminars, and 2 first-author & 2 co-author publications ● Selected from over 200 abstract submissions to be featured in a pre-conference press release advertising the American Association of Pharmaceutical Scientists (AAPS) 2017 National Conference ● Recognized as a T32 fellow in the UAMS Systems Pharmacology and Toxicology program

● Developed reproducible, reliable, and accurate assay protocols, analyzed the data using Graphpad Prism, and mentored 3 summer and rotating students in assay design and theory● Performed aseptic tissue culturing & transfection in human cell lines and immunoassays (flow cytometry, ELISA, immunoprecipitation, and western-blots) to identify 2 novel auto-antigens/biomarkers in patients with systemic lupus erythematosus (SLE)

● Performed molecular cloning & Sanger sequencing and developed phylogenetic tree models in order to differentiate species of fire coral showing phenotypic plasticity; managed and mentored 2 junior lab students● Presented data in poster presentations at 4 local conferences and contributed to 3 professional publications